Developer docs
API playgroundTry for free, no card

Search company profiles

Kintara Therapeutics

Full company profile

uuid000515n

Namestring
Kintara Therapeutics
Legal namestring
Kintara Therapeutics Inc.
Websiteurl
kintara.com
Company typeenum
Public
Founded yearint
2010
Descriptiontext

Kintara Therapeutics Inc. was a publicly traded clinical-stage biopharmaceutical company focused on developing therapies for cancer patients, headquartered in Vancouver, Canada, and incorporated in the United States. The company built its pipeline around two distinct drug candidates: REM-001, a photodynamic therapy that uses light-activated compounds to selectively destroy cancer cells in cutaneous metastatic breast cancer lesions, and VAL-083, a chemotherapy agent for cancer treatment. Both assets were in clinical development, with REM-001 supported by a $2.0 million NIH SBIR grant awarded in June 2023 to generate clinical evidence for a Phase 3 study design.

The company's business model was pre-commercial: Kintara generated no product revenue and instead funded operations through a combination of equity financing (notably a $20 million committed share purchase agreement with Lincoln Park Capital in August 2022) and non-dilutive grants. Its GTM motion consisted of scientific conference presentations, press releases, and regulatory filings rather than traditional sales channels, and distribution was planned for post-approval through pharmaceutical channels.

In December 2025, REM-001 met its primary safety endpoint in a clinical trial, triggering the release of contingent value right (CVR) shares and confirming the company's acquisition by TuHURA Biosciences. Prior to that, Kintara had pursued pipeline expansion through acquisitions, including Adgero Biopharmaceuticals in June 2020, and operated with a lean team of 1-10 employees. The acquisition transitioned Kintara from an independent public entity into a wholly-controlled subsidiary of TuHURA Biosciences.

Short descriptiontext

Kintara Therapeutics was a pre-revenue, publicly traded clinical-stage biopharmaceutical company developing REM-001 photodynamic therapy for cutaneous metastatic breast cancer and VAL-083 chemotherapy, acquired by TuHURA Biosciences in December 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
oncology drug development, photodynamic therapy, cancer therapeutics, biopharmaceutical development, clinical stage oncology
Industry1 code
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Therapeutics
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kintara Therapeutics is a clinical-stage biopharmaceutical company developing two cancer drug candidates: REM-001, a photodynamic therapy designed to treat cutaneous metastatic breast cancer, and VAL-083, a chemotherapy agent under development for cancer treatment. Both assets are in the clinical pipeline, with REM-001 advancing toward a Phase 3 study following NIH SBIR grant support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • REM-001 met primary safety endpoint in clinical trial (December 2025)
Product overview1 text field

Kintara Therapeutics is a biopharmaceutical company developing two distinct cancer therapies. REM-001 is a photodynamic therapy in clinical development for cutaneous metastatic breast cancer, recently supported by a $2.0 million NIH SBIR grant to generate clinical evidence for a Phase 3 study. VAL-083 is a chemotherapy agent also under development for cancer treatment. Both products are in the clinical development pipeline and have received funding support, including a $20 million equity financing agreement with Lincoln Park Capital for working capital and development expenses.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Following Kintara's merger/acquisition by TuHURA Biosciences, Kintara's REM-001 clinical trial met its primary safety endpoint in December 2025, resulting in the release of contingent value rights (CVR) shares. Approximately 1.54 million shares of TuHURA stock were distributed to legacy Kintara stockholders as a result of this milestone achievement.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage oncology biopharma developing novel therapeutics including a photodynamic therapy asset (Validive). Comparable in modality, stage, and small-cap profile to Kintara.

TypeDirect peer
Description

Commercial-stage photodynamic therapy company (Hexvix/Cysview) for bladder cancer. Closest pure-play peer in the PDT oncology space, sharing the same light-activated mechanism as REM-001.

TypeDirect peer
Description

Developer of Tookad, a vascular-targeted photodynamic therapy for prostate cancer. Direct PDT modality peer with similar mechanism and oncology focus.

TypeDirect peer
Description

Clinical-stage company developing photodynamic therapy (TLD-1433) for non-muscle invasive bladder cancer. Direct PDT peer with comparable small-cap clinical-stage profile.

TypeDirect peer
Description

Late-stage clinical biopharma developing oncology and rare disease therapeutics. Comparable as a small clinical-stage biotech with limited headcount and dual-asset pipeline.

TypeDirect peer
Description

Clinical-stage oncology biotech developing small-molecule therapies for hard-to-treat tumors. Comparable in scale, stage, and pre-revenue clinical development model.

TypeDirect peer
Description

Clinical-stage oncology company developing small-molecule therapies with a lead asset in metastatic colorectal cancer. Similar pre-revenue clinical profile and small-cap public status.

TypeDirect peer
Description

Small-cap oncology biotech developing kinase inhibitors for hematologic cancers and solid tumors. Comparable as a publicly traded clinical-stage oncology company of similar size.

TypeOthers
Description

Medical laser technology company whose devices enable photodynamic therapy delivery. Enabler/adjacent company providing infrastructure for PDT procedures like REM-001.

TypeBroad incumbent
Description

Established targeted oncology biotech (acquired by Bristol-Myers Squibb) developing small-molecule oncology therapies. Comparable modality (targeted small molecules) at later commercial stage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kintara Therapeutics

Oncology Therapeuticskintara.com

Kintara Therapeutics was a pre-revenue, publicly traded clinical-stage biopharmaceutical company developing REM-001 photodynamic therapy for cutaneous metastatic breast cancer and VAL-083 chemotherapy, acquired by TuHURA Biosciences in December 2025.

What Kintara Therapeutics does

Kintara Therapeutics Inc. was a publicly traded clinical-stage biopharmaceutical company focused on developing therapies for cancer patients, headquartered in Vancouver, Canada, and incorporated in the United States. The company built its pipeline around two distinct drug candidates: REM-001, a photodynamic therapy that uses light-activated compounds to selectively destroy cancer cells in cutaneous metastatic breast cancer lesions, and VAL-083, a chemotherapy agent for cancer treatment. Both assets were in clinical development, with REM-001 supported by a $2.0 million NIH SBIR grant awarded in June 2023 to generate clinical evidence for a Phase 3 study design.

The company's business model was pre-commercial: Kintara generated no product revenue and instead funded operations through a combination of equity financing (notably a $20 million committed share purchase agreement with Lincoln Park Capital in August 2022) and non-dilutive grants. Its GTM motion consisted of scientific conference presentations, press releases, and regulatory filings rather than traditional sales channels, and distribution was planned for post-approval through pharmaceutical channels.

In December 2025, REM-001 met its primary safety endpoint in a clinical trial, triggering the release of contingent value right (CVR) shares and confirming the company's acquisition by TuHURA Biosciences. Prior to that, Kintara had pursued pipeline expansion through acquisitions, including Adgero Biopharmaceuticals in June 2020, and operated with a lean team of 1-10 employees. The acquisition transitioned Kintara from an independent public entity into a wholly-controlled subsidiary of TuHURA Biosciences.

Kintara Therapeutics firmographics

Firmographics
Name
Kintara Therapeutics
Legal name
Kintara Therapeutics Inc.
Website
https://kintara.com
Company type
Public
Founded year
2010
Operating status
Acquired
Headcount range
1–10 employees
Short description
Kintara Therapeutics was a pre-revenue, publicly traded clinical-stage biopharmaceutical company developing REM-001 photodynamic therapy for cutaneous metastatic breast cancer and VAL-083 chemotherapy, acquired by TuHURA Biosciences in December 2025.
Ownership category
akta.pro rank

Kintara Therapeutics industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Oncology drug development
  • Photodynamic therapy
  • Cancer therapeutics
  • Biopharmaceutical development
  • Clinical stage oncology

Where Kintara Therapeutics is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Markets served

Kintara Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Marketing channels2 records

Kintara Therapeutics product offering

Product offering

Core offering

Kintara Therapeutics is a clinical-stage biopharmaceutical company developing two cancer drug candidates: REM-001, a photodynamic therapy designed to treat cutaneous metastatic breast cancer, and VAL-083, a chemotherapy agent under development for cancer treatment. Both assets are in the clinical pipeline, with REM-001 advancing toward a Phase 3 study following NIH SBIR grant support.

Product overview

Kintara Therapeutics is a biopharmaceutical company developing two distinct cancer therapies. REM-001 is a photodynamic therapy in clinical development for cutaneous metastatic breast cancer, recently supported by a $2.0 million NIH SBIR grant to generate clinical evidence for a Phase 3 study. VAL-083 is a chemotherapy agent also under development for cancer treatment. Both products are in the clinical development pipeline and have received funding support, including a $20 million equity financing agreement with Lincoln Park Capital for working capital and development expenses.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • REM-001 met primary safety endpoint in clinical trial (December 2025)

Companies that use Kintara Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Kintara Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Kintara Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • TuHURA BiosciencescoreStrategic or Co-development PartnerFollowing Kintara's merger/acquisition by TuHURA Biosciences, Kintara's REM-001 clinical trial met its primary safety endpoint in December 2025, resulting in the release of contingent value rights (CVR) shares. Approximately 1.54 million shares of TuHURA stock were distributed to legacy Kintara stockholders as a result of this milestone achievement.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Kintara Therapeutics competitors and assessment

Company assessment

Direct peers

  • Onxeo: Clinical-stage oncology biopharma developing novel therapeutics including a photodynamic therapy asset (Validive). Comparable in modality, stage, and small-cap profile to Kintara.
  • Photocure: Commercial-stage photodynamic therapy company (Hexvix/Cysview) for bladder cancer. Closest pure-play peer in the PDT oncology space, sharing the same light-activated mechanism as REM-001.
  • Steba Biotech: Developer of Tookad, a vascular-targeted photodynamic therapy for prostate cancer. Direct PDT modality peer with similar mechanism and oncology focus.
  • Theralase Technologies: Clinical-stage company developing photodynamic therapy (TLD-1433) for non-muscle invasive bladder cancer. Direct PDT peer with comparable small-cap clinical-stage profile.
  • Soligenix: Late-stage clinical biopharma developing oncology and rare disease therapeutics. Comparable as a small clinical-stage biotech with limited headcount and dual-asset pipeline.
  • Moleculin Biotech: Clinical-stage oncology biotech developing small-molecule therapies for hard-to-treat tumors. Comparable in scale, stage, and pre-revenue clinical development model.
  • Cardiff Oncology: Clinical-stage oncology company developing small-molecule therapies with a lead asset in metastatic colorectal cancer. Similar pre-revenue clinical profile and small-cap public status.
  • Verastem Oncology: Small-cap oncology biotech developing kinase inhibitors for hematologic cancers and solid tumors. Comparable as a publicly traded clinical-stage oncology company of similar size.

Others

  • Lumenis (LightMed/Biolitec): Medical laser technology company whose devices enable photodynamic therapy delivery. Enabler/adjacent company providing infrastructure for PDT procedures like REM-001.

Broad incumbents

  • Mirati Therapeutics: Established targeted oncology biotech (acquired by Bristol-Myers Squibb) developing small-molecule oncology therapies. Comparable modality (targeted small molecules) at later commercial stage.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

Kintara Therapeutics social profiles

Digital presence

Kintara Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kintara Therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

Kintara Therapeutics funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kintara Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kintara Therapeutics

What does Kintara Therapeutics do?

Kintara Therapeutics is a clinical-stage biopharmaceutical company developing two cancer drug candidates: REM-001, a photodynamic therapy designed to treat cutaneous metastatic breast cancer, and VAL-083, a chemotherapy agent under development for cancer treatment. Both assets are in the clinical pipeline, with REM-001 advancing toward a Phase 3 study following NIH SBIR grant support.

Is Kintara Therapeutics a public or private company?

Kintara Therapeutics is a public company. It is classified as public and is currently acquired.

When was Kintara Therapeutics founded?

Kintara Therapeutics was founded in 2010. It employs 1 to 10 people.

Where is Kintara Therapeutics based?

Kintara Therapeutics is headquartered in Vancouver, Canada, in the North America region.

Who are Kintara Therapeutics's main competitors?

Direct peers on record are Onxeo, Photocure, Steba Biotech, Theralase Technologies, Soligenix, Moleculin Biotech, Cardiff Oncology and Verastem Oncology. Lumenis (LightMed/Biolitec) is listed as an others. Mirati Therapeutics is listed as a broad incumbent.

Does Kintara Therapeutics have an API?

No public API is recorded for Kintara Therapeutics.

What industry is Kintara Therapeutics in?

Kintara Therapeutics's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TuhurabioTuHURA Biosciences Completes Merger Transaction with Kintara TherapeuticsTuHURA Biosciences has completed its merger with Kintara Therapeutics, forming a combined entity that will operate under the name TuHURA Biosciences and trade on Nasdaq under the ticker 'HURA'. The new company secured $31 million in fully-funded financing to support operations through late 2025 and plans to initiate a Phase 3 registration trial for its lead cancer immunotherapy candidate, IFx-2.0, in the first half of 2025.PR NewswireKintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024Kintara Therapeutics issued a correction to its prior announcement regarding the record date for Contingent Value Rights (CVRs) in connection with its proposed merger with TuHURA Biosciences. The company clarified that CVRs will be issued to stockholders of record immediately prior to the planned reverse stock split, rather than on the previously stated October 17 date. The merger is expected to close on October 18, 2024, subject to regulatory approval.PR NewswireTuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor CancerKineta reopened enrollment in its VISTA-101 Phase 1/2 trial for KVA12123, with 30 of 39 projected patients enrolled. The trial includes monotherapy and combination arms with KEYTRUDA, and TuHURA is conducting due diligence under an agreement. Kineta expects full enrollment by end of 2024.PR NewswireKintara Therapeutics Announces Fiscal 2024 Third Quarter Financial ResultsKintara Therapeutics announced fiscal Q3 2024 financial results showing a reduced net loss of $2.0 million compared to $3.3 million in Q3 2023, with cash and cash equivalents of $6.35 million as of March 31, 2024. The company also announced a definitive merger agreement with TuHURA Biosciences and Kayak Mergeco, Kintara's wholly-owned subsidiary, with TuHURA to survive as Kintara's direct wholly-owned subsidiary, expected to close in Q3 2024. Under the terms, Kintara's existing stockholders are expected to own approximately 2.85% (or 5.45% including CVR shares if a milestone is achieved) of the post-Merger combined company on a fully-diluted basis.PR NewswireSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRAMonteverde & Associates PC, a New York-based M&A class action law firm, announced an investigation into Kintara Therapeutics, Inc. regarding its proposed merger with TuHURA Biosciences, Inc., seeking to determine whether the transaction is fair to shareholders. The law firm is offering free consultations to shareholders who own common stock in Kintara and wish to obtain additional information about the investigation. This type of stockholder investigation is a routine legal marketing announcement commonly issued when mergers are pending.PR NewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, SCX, KTRAHalper Sadeh LLC is investigating Model N, Inc., The L.S. Starrett Company, and Kintara Therapeutics, Inc. for potential violations related to their recent transactions. Model N is being scrutinized for its sale to Vista Equity Partners for $30.00 per share, Starrett's sale to MiddleGround Capital for $16.19 per share, and Kintara's merger with TuHURA Biosciences. The firm seeks to ensure shareholders' rights are protected and may pursue increased compensation or disclosures.PR NewswireShareholder Alert: Ademi LLP investigates whether Kintara Therapeutics, Inc. has obtained a Fair Price in its transaction with TuHURALaw firm Ademi LLP announced an investigation into Kintara Therapeutics (Nasdaq: KTRA) regarding its transaction with TuHURA, citing possible breaches of fiduciary duty by Kintara's board of directors. In the proposed transaction, existing Kintara stockholders would retain only approximately 2.85% of the combined company while TuHURA equityholders would own approximately 97.15%, with Kintara insiders receiving substantial benefits under change of control arrangements. The law firm is seeking additional Kintara shareholders to join potential litigation against the company's board.BenzingaWhy Kintara Therapeutics Shares Are Gaining TodayKintara Therapeutics entered into a definitive merger agreement with TuHURA Biosciences, resulting in the combined entity operating under the name TuHURA Biosciences and trading on the Nasdaq under the ticker "HURA". The merged company will focus on advancing personalized cancer vaccines and bi-functional ADCs, supported by a $31 million subscribed financing expected to fund operations through late 2025.PR NewswireKintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger AgreementKintara Therapeutics and TuHURA Biosciences have entered into a definitive merger agreement to form a combined company operating under the name TuHURA Biosciences, with an expected close in the third quarter of 2024. The transaction includes a $31 million subscribed financing for TuHURA, providing cash runway through late 2025 to advance its Phase 3 clinical trials for the IFx-2.0 cancer vaccine.